ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - Alector, Inc. is under investigation by the Schall Law Firm for potential violations of securities laws following disappointing results from a clinical trial, which led to a significant drop in its stock price [2][3]. Group 1: Investigation Details - The Schall Law Firm is investigating claims on behalf of Alector investors regarding false or misleading statements made by the company [2]. - Alector's press release on October 21, 2025, revealed that its drug candidate, latozinemab (AL001), failed to meet the primary endpoint in a Phase 3 clinical trial for frontotemporal dementia, resulting in a nearly 50% drop in share price the following day [2][3]. Group 2: Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and is encouraging affected shareholders to participate in the investigation [3]. - Investors can contact the Schall Law Firm for a free discussion about their rights [3].